Memorial Sloan Kettering Cancer Center’s Oric Pharmaceuticals ORIC Stock Holding History

Memorial Sloan Kettering Cancer Center’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$3.64M	Hold	602,272	–	–	14.84%	2
2023 Q2	$4.67M	Hold	602,272	–	–	14.75%	2
2023 Q1	$3.43M	Hold	602,272	–	–	10.53%	2
2022 Q4	$3.55M	Hold	602,272	–	–	11.7%	2
2022 Q3	$1.93M	Hold	602,272	–	–	6.55%	4
2022 Q2	$2.7M	Hold	602,272	–	–	8.92%	4
2022 Q1	$3.22M	Hold	602,272	–	–	3.72%	4
2021 Q4	$8.85M	Hold	602,272	–	–	5.56%	4
2021 Q3	$12.6M	Hold	602,272	–	–	7.85%	4
2021 Q2	$10.7M	Hold	602,272	–	–	6.97%	3
2021 Q1	$14.8M	Hold	602,272	–	–	9.09%	3
2020 Q4	$20.4M	Buy	+602,272	New	+$17.3M	8.63%	3

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Alkeon Capital Management

Alkeon Capital Management New York $22.1B AUM 51.63% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return